Prana Biotech (PRAN) – Press Releases
-
Prana Receives First Orphan Drug Designation from the FDA for the Treatment of Multiple System Atrophy
-
Life Biosciences LLC leads strategic investment of up to A$44.5 million (US$31.4 million) in Prana
-
Prana Biotechnology: Pre-Clinical Evidence Demonstrates PBT434 as a Potential Treatment for MSA
-
PBT434 Data to be Presented at the International Congress of Parkinson’s Disease and Movement Disorders
-
First Volunteers Dosed in Phase I Clinical Trial of PBT434, Prana’s Lead Therapy for Parkinsonian Diseases
-
Prana to Commence Phase 1 Clinical Trial of PBT434 for Treatment of Parkinsonian Diseases
-
Prana Commences Research Collaboration with Takeda for the Treatment of Parkinson's Disease Gastrointestinal Neuropathology
-
Prana's PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration
-
Prana Appoints David Stamler as Chief Medical Officer to Lead Clinical Development
-
New Data from Reach2HD Trial Presented at American Neurological Association Annual Meeting
-
Prana Alzheimer's disease data features at world leading conference
-
Prana Regains Compliance with NASDAQ Continued Listing Requirements Continues to Work Towards FDA Submission
-
Prana Biotechnology Half Year Investor Report
-
Nohla Therapeutics Closes Oversubscribed US $21M Private Financing Round and Strengthens Board with New Appointment
-
Prana Chief Scientific Advisor Receives Smithsonian American Ingenuity Award
-
Prana Receives Non-Compliance Notice Regarding NASDAQ Minimum Bid Price Requirement
-
Prana Reports FY15 Financial Results
-
Prana Announces Safety Outcomes of Alzheimer’s IMAGINE Extension Trial
-
European Commission Approves PBT2 Orphan Designation for Huntington’s Disease
-
PBT2 Recommended for Orphan Designation in Europe
Back to PRAN Stock Lookup
